MAP2K7 and melanoma: The results from the DOC-MEK Phase II trial in BRAF wild-type advanced melanoma patients13 demonstrated that docetaxel plus selumetinib did not significantly increase PFS or OS compared with docetaxel plus placebo, but there was a trend towards increased ORR in the selumetinib group (P = 0.059).